Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer’s Disease via Neuroinflammation and Ferroptosis

Jiahui Yang, Xiaohua Shi, Yingying Wang, Ming Ma, Hongyu Liu, Jiaoqi Wang and Zhongxin Xu*
Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China

Accepted 18 September 2023

Abstract. Alzheimer’s disease (AD) is the main cause of dementia in older age. The prevalence of AD is growing worldwide, causing a tremendous burden to societies and families. Due to the complexity of its pathogenesis, the current treatment of AD is not satisfactory, and drugs acting on a single target may not prevent AD progression. This review summarizes the multi-target pharmacological effects of thiazolidinediones (TZDs) on AD. TZDs act as peroxisome proliferator-activated receptor gamma (PPARγ) agonists and long-chain acyl-CoA synthetase family member 4 (ACSL4) inhibitors. TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD. Here, we discussed recent findings from clinical trials of pioglitazone in the treatment of AD, ischemic stroke, and atherosclerosis. We also dissected the major limitations in the clinical application of pioglitazone and explained the potential benefit of pioglitazone in AD. We recommend the use of pioglitazone to prevent cognitive decline and lower AD risk in a specific group of patients.

Keywords: Alzheimer’s disease, ferroptosis, multi-target, neuroinflammation, thiazolidinediones

INTRODUCTION

Alzheimer’s disease (AD) is the main cause of dementia in older age and its prevalence is growing worldwide. By 2050, the global prevalence of dementia will triple [1]. Currently, pharmaceutical companies are attempting to develop AD drugs mainly based on the amyloid cascade hypothesis. However, many drugs targeting amyloid-β (Aβ) failed to demonstrate clinical efficacy. Aducanumab, an anti-Aβ antibody, was recently granted FDA approval. Although it removes Aβ plaques in patients with AD, it does not sufficiently improve brain function and cognition, nor prevent AD progression [2]. With the development of neuroimaging, neuropathology, and biomarkers, a growing body of evidence suggests that AD is a neurodegenerative disease with complex and multifactorial etiology [3, 4].

Typical pathological changes of AD include diffuse precipitation of extracellular Aβ plaques and intracellular neurofibrillary tangles (NFTs). Aβ peptides are produced by sequential cleavage of Aβ precursor protein (AβPP) by β-site AβPP cleaving enzyme 1 (BACE1) and γ-secretase complex. They are released into extracellular space and aggregated into oligomers and fibrils [5]. The 42-amino acid form (Aβ1–42) of Aβ is its most toxic form, which can directly damage neurons by binding to neuron-specific receptors or altering membrane lipid permeability [6, 7]. NFTs are the abnormal aggregation of hyperphosphorylated tau proteins, which hinder microtubules assembly and impair axonal transport in synapses [8]. In 1991, Braak found that the distribution pattern and packing density of Aβ...
peptides turned out to be limited for differentiation of neuropathological stages. In contrast, NFTs exhibited a characteristic distribution pattern permitting the differentiation of six stages, which called Braak-like pattern [9, 10]. The spatial and temporal pattern in the appearance of these NFTs correlates with cognitive decline as well as brain atrophy [3, 11, 12].

A growing number of studies have confirmed that neuroinflammation plays an important role in the pathogenesis of AD. The deposition of Aβ peptides drives neuroinflammation by activating microglia. When NLRP3 inflammasome assembles inside of microglia, its activation will promote Aβ deposition and drive tau pathology. Meanwhile, microglia are involved in the processing and spreading of tau [13–15]. Pascoal found microglial activation and tau accumulation colocalize in a Braak-like pattern in the living human brain with positron emission tomography brain imaging, and tau propagation pathways depended on the baseline microglia network rather than the tau network. Their findings support a model where an interaction between Aβ and activated microglia sets the pace for tau spread across Braak stages [16].

Ferroptosis is a newly discovered programmed cell death characterized by iron dyshomeostasis and lipid peroxidation, which was reminiscent of AD. In addition to the accumulation of Aβ plaques, NFTs, and neuroinflammation, AD patients show progressive synaptic loss, and neuronal death, also high oxidative stress that correlates with abnormal levels or overload of brain metals [17]. Cortical iron has been shown to be elevated in AD, the level of cortical iron was strongly associated with cognitive decline in AD [18]. Cortical iron might propel cognitive deterioration by inducing oxidative stress and ferroptosis, suggesting anti-ferroptotic therapies may be efficacious in AD.

The complex pathophysiology of AD necessitates the simultaneous pursuit of multiple targets for successful treatment. However, multi-target drugs generally have poor specificity and diminished efficacy [19]. TZDs are a group of anti-diabetic drugs that improve insulin resistance [20, 21]. TZDs, including troglitazone, rosiglitazone, and pioglitazone, can suppress the inflammatory response and cell ferroptosis with high target specificity. Therefore, in addition to their use in diabetes, researchers administered TZDs in the preclinical and clinical studies of AD. In addition to the pharmacological targets of TZDs, we discuss the neuroprotective effects of TZDs on AD, which is mainly mediated by inhibiting neuroinflammation and ferroptosis.

PHARMACOLOGICAL TARGETS OF TZDS

PPARγ

PPARγ is a member of the peroxisome proliferator-activated receptors (PPARs) family, which consists of three isoforms: PPARα, PPARδ, and PPARγ. PPARγ functions in a ligand-dependent manner [19, 22]. Endogenous polyunsaturated fatty acids (PUFAs) act as the natural ligand of PPARγ, with a low affinity. TZDs are exogenous strong activators of PPARγ due to their high affinity (Fig. 1) [23]. Through transactivation, agonist-bound PPARγ positively regulates cell metabolic homeostasis, including adipogenesis, fat storage, insulin sensitization, and cellular differentiation. Anti-inflammatory properties of PPARγ are regulated by transrepression, not transactivation.

Neuroinflammation is the immune response of the central nervous system (CNS) to various harmful stimuli. In AD, neuroinflammation is primarily mediated by immune cells in the CNS. Activated microglia, reactive astrocytes, and increased levels of proinflammatory cytokines are involved in neuroinflammation [24–26]. Agonist-bound PPARγ inhibits neuroinflammation by antagonizing the function of inflammation-related transcription factors, such as nuclear factor-κB (NF-κB), activator protein-1 (AP-1), JAK/STAT, and nuclear factors of activated T-cells (NFAT) [27–29]. Three principal transrepression mechanisms have been proposed. First, activated PPARγ competitively binds most of the coactivators, making them unavailable for other transcription factors. Second, PPARγ directly binds to other transcription factors, preventing them from inducing gene transcription. Third, PPARγ inhibits the activation of mitogen-activated protein kinase (MAPK), thereby inhibiting downstream transcription factors. Among them, NF-κB is the main target for PPARγ, which is involved in the expression of numerous inflammatory factors and pro-inflammatory mediators (Fig. 2) [22].

ACSL4

Acyl-CoA synthetases (ACS) convert fatty acids to their respective acyl-CoA-activated forms, which are involved in energy metabolism and membrane structure. Non-activated free fatty acids are involved in the production of bioactive mediators such as prostaglandins (PGs), leukotrienes (LTs), and thromboxane (TX) [30]. Among the ACS family,
Fig. 1. Timeline diagram depicting mechanism-based studies, clinical application, and clinical trials of TZDs.

Fig. 2. Neuroinflammation in the pathogenesis of AD. Soluble Aβ oligomers bind to Aβ receptors (Aβ-R) on microglia, which will be subsequently internalized and degraded. Activated microglia secrete proinflammatory factors through NF-xB signaling pathway to amplify microglial activation and phagocytosis. Aβ aggregation due to overproduction or impaired phagocytosis, continuously activates microglia and astrocytes. M1 microglia and A1 astrocytes secrete proinflammatory cytokines (IL-1β, IL-6, IL-18, and TNFα), ROS, complement C3, and neurotoxin, which can accelerate neuronal damage, expand inflammatory response, and promote Aβ deposition and NFTs formation. Activated microglia participate in the spread of pathological tau through the exosome pathway.
long-chain acyl-CoA synthetases (ACSLs) consume a broad range of long-chain fatty acid substrates from 10 to 22 carbons, as their substrate. ACSLs consist of five ACSL isozymes, including ACSL1, ACSL5, ACSL6, ACSL3, and ACSL4. They are classified based on sequence homology and substrate specificities. For instance, ACSL4 especially prefers PUFAs [31]. The study found that TZDs could specifically inhibit ACSL4 in a PPARγ-independent manner (Figs. 1 and 3) [32]. PUFAs refer to long-chain fatty acids with more than two double bonds. PUFAs are susceptible to lipid peroxidation because of weak C–H bonds at the bis-allylic positions [33].

Ferroptosis is a recently identified form of non-apoptotic cell death. Ferroptosis is caused by iron-dependent peroxidation of lipids and plays an important role in AD [34, 35]. Membrane phospholipids containing PUFAs (PUFA-PLs) are pivotal for ferroptosis. Blocking the peroxidation site of PUFAs could prevent ferroptosis [36]. ACSL4 is a key enzyme for ferroptosis, activating PUFA to form PUFA-COA, which will be esterified to PUFA-PLs. TZDs, as specific inhibitors of ACSL4, directly inhibit PUFAs incorporation into cellular lipids in a PPARγ-independent manner. 10 μM concentration of troglitazone, rosiglitazone, or pioglitazone could inhibit 85–95% function of ACSL4. Rosiglitazone inhibited PUFAs incorporation into cellular lipids in a PPARγ-independent manner. 10 μM concentration of troglitazone, rosiglitazone, or pioglitazone could inhibit 85–95% function of ACSL4. Rosiglitazone had the strongest inhibitory effect, comparable to ACSL4 knockout, and effectively prevented ferroptosis [31, 32]. Unlike ACSL4 deletion, deletion of other members of ACSL did not affect ferroptosis [31].

TZDS INHIBIT NEUROINFLAMMATION IN AD

Cell players of neuroinflammation

Microglia

Microglia, the resident phagocytes of the CNS, are widely distributed in the brain. Microglia are the main driver of neuroinflammation. In physiological conditions, microglia play an important role in the maintenance and plasticity of neuronal circuits and contribute to synaptic remodeling. Meanwhile, microglia use constantly motile processes to find pathogens, cellular debris, or misfolded proteins. Once activated by these pathological factors, microglia initiate phagocytosis to maintain CNS homeostasis [6].

The soluble Aβ aggregates in AD bind to cell-surface receptors of microglia (Fig. 2), including CD36, CD47, α6β1-integrin, and toll-like receptors (TLRs). This receptor-ligand interaction activates phagocytic uptake of Aβ by microglia. Internalized Aβ fibers are degraded by lysosomal proteases [37, 38]. Microglial activation simultaneously induces a variety of phenotypes. The classic M1 phenotype of microglia, also known as the proinflammatory phenotype, is characterized by increased secretion of proinflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-12, and IL-18. M1 microglia also release reactive oxygen species (ROS) and nitrogen oxide (NO) with less phagocytosis. The classic M2 phenotype of microglia, also known as the anti-inflammatory phenotype, releases anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β). M2 microglia has outstanding phagocytosis ability, with no toxic products. The M1 and M2 are the extremes of microglial phenotype. There may be a series of transitional phenotypes, which collectively participate in local immune responses in the brain [39, 40]. Activated microglia upregulate NLRP3 inflammasome and release IL-1β and IL-18 through NF-κB signaling pathway [13, 41]. IL-1β is a potent proinflammatory cytokine, which binds to the IL-1β receptor (IL-1R) on neurons and glial cells, activates the classical NF-κB and MAPK signaling pathways, thereby upregulating itself and other proinflammatory cytokines, such as TNF-α and IL-6 (Fig. 2) [42]. In addition, IL-1β induces an M1-like phenotype of microglia to release more proinflammatory factors and ROS [6].

Similar to the effect of PPARγ activation on mononuclear macrophages in peripheral tissues, TZDs inhibit the nuclear translocation of NF-κB by activating PPARγ, and induce microglia transformation from the proinflammatory M1 to the anti-inflammatory M2 phenotype in the CNS [43]. Consistently, pioglitazone decreased the expression of IL-1β, IL-6, and TNF-α, and promoted the expression of IL-4, IL-10, and TGF-β in neuroinflammation [44, 45]. The expression of NLRP3 and IL-1β significantly decreased following treatment with pioglitazone, which protected neurons against microglial NO [46, 47]. Furthermore, pioglitazone upregulated the expression of the microglial cell-surface scavenging receptor, CD36, and enhanced Aβ phagocytosis [48, 49].

Astrocytes

Astrocytes are the most important supporting cells in CNS. They are involved in a variety of physiological functions, including secretion of trophic
molecules, regulation of brain microenvironment, maintenance of blood-brain barrier (BBB) integrity, and normal function of synapses [50]. Zamanian et al. used inflammatory and ischemia models to induce two different types of reactive astrocytes and found that inflammation-induced reactive astrocytes upregulated a variety of “harmful” genes, named type A1 astrocytes, while ischemia-induced reactive astrocytes upregulated a variety of “beneficial” genes, named type A2 astrocytes [51].

In neuroinflammation, microglia induce A1 astrocytes by releasing three main cytokines, IL-1α, TNFα, and complement component subunit 1Q (C1q) [52]. A1 astrocytes cannot support neuronal survival, outgrowth, synaptogenesis, and phagocytosis [50]. Similar to M1 microglia, A1 astrocytes upregulate inflammatory markers such as TNFα, IL-1β, IL-6, ROS, and complement component C3 through NF-κB signaling pathway. Complement C3 activates neuronal C3aR to disrupt the morphology and function of dendrites [53]. Moreover, complement C3 can be specifically used as a marker of reactive A1 astrocytes [52]. A1 phenotype simultaneously secretes a neurotoxin that can induce apoptosis in neurons and oligodendrocytes (Fig. 2) [25].

A1 astrocytes reside around Aβ plaques. Rosiglitazone significantly reduced the intensity of glial fibrillary acidic protein (GFAP) staining and the number of A1 astrocytes and promoted the functional recovery of astrocytes [54–56]. Pioglitazone downregulated IL-1β, IL-6, TNF-α, COX2, and iNOX in astrocytes through the PPARγ/NF-KB pathway, thereby alleviating neuroinflammation [57–59].

**Neuroinflammation regulate Aβ and tau pathology**

In the early stages of AD, microglia release inflammatory cytokines and chemokines to recruit more microglia and astrocytes for phagocytic degradation of Aβ. However, when Aβ accumulation exceeds the phagocytosis capacity of microglia, or when the phagocytosis capacity of microglia is impaired due to the presence of APOE4 or TREM2 variants, Aβ accumulates in the extracellular space and directly damages neurons (Fig. 2) [60, 61]. Normal astrocytes can degrade Aβ by releasing proteases, which play an important role in Aβ clearance. Impaired function and atrophy of reactive astrocytes might contribute to reduced clearance of Aβ [62]. The proinflammatory factors secreted by activated microglia and reactive astrocytes can promote AβPP synthesis and BACE1 expression, thereby enhancing Aβ deposition [63, 64]. Due to the continuous positive feedback loop between Aβ and neuroinflammation, chronic inflammatory response activates microglia and astrocytes in AD [26].

Radiotracer detection method revealed active neuroinflammation in the tau aggregation area [65]. Proinflammatory factors released by activated microglia and reactive astrocytes play an important role in tau pathology. It was demonstrated that tau-hypophosphorylation and aggregation depend on NLRP3 inflammasome in mice treated with intracerebral Aβ [14]. In a mouse model of AD with IL-1β overexpression, it was found that IL-1β promotes tau phosphorylation through p38-MAPK and glyco-gen synthase kinase 3 (GSK-3β) signaling pathways [66, 67]. TNFα-treated neurons induce tau aggregation through ROS generation. Similarly, activated microglia co-cultured with neurons induce tau aggregation (Fig. 2) [68]. Current findings support that pathological tau seeds can spread between neurons and induce hyperphosphorylated tau aggregation in normal neurons [69]. Activated microglia remove pathological tau seeds and cell debris in the interstitial fluid. Some will be degraded, and the others will be re-released in exosomes (Fig. 2). Inhibition of exosome synthesis or depletion of microglia can significantly restrain the spread of pathological tau, suggesting that microglia may participate in the progression of pathological tau through exosome release [70].

**TZDs improve AD by regulating neuroinflammation**

TZDs were first used for AD after discovering that non-steroidal anti-inflammatory drugs (NSAIDs) can activate PPARγ [71]. Epidemiological studies have found that long-term use of NSAIDs can significantly reduce the risk of AD [72]. Subsequently, animal studies confirmed that long-term administration of ibuprofen significantly reduces soluble Aβ1–42 levels and cortical Aβ plaques and prevents microglial activation in 11-month-old Tg2576 mice [73]. PPARγ antagonist also attenuated the protective effect of ibuprofen on Aβ deposition [63]. Given that NSAIDs may inhibit neuroinflammation and disease progression in AD by activating PPARγ, TZDs, as strong activators of PPARγ, are potential candidates for treating AD [74].

Heneka et al. compared the efficacy of pioglitazone and ibuprofen in 10-month-old AβPP V717I
mice. Both treatments significantly reduced the number of activated microglia and reactive astrocytes, downregulated COX2, iNOS, and BACE1, and prevented Aβ\textsubscript{1–42} deposition in the hippocampus and cortex (Fig. 1) [74]. Similarly, in mice overexpressing mutant human AβPP, rosiglitazone activated M2 microglia to promote its phagocytic ability, reduce the expression of proinflammatory markers, and remove Aβ plaques and neuropil threads containing phosphorylated tau in the hippocampus [75]. Pioglitazone blocks Aβ-triggered hyperphosphorylated of tau and the subsequent synaptic loss [76]. In addition to improving AD pathology and inflammation in the brain, pioglitazone and rosiglitazone both improved spatial memory impairment in mice induced by Aβ [48, 56].

It has been found that TZDs can also affect AD pathology through PPAR\textgamma-dependent non-inflammatory pathways. Researchers identified a PPAR\textgamma-responsive element (PPRE) in the BACE1 gene promoter, which controls BACE1 expression. PPAR\textgamma could be a repressor of BACE1, since over-expression of PPAR\textgamma or treatment with pioglitazone reduces BACE1 expression and intracellular Aβ levels, while PPAR\textgamma depletion enhances BACE1 gene promoter activity [77]. Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase with many important roles in neuronal development. Enhanced CDK5 activity was observed in mice models of AD, which may be related to Aβ-induced dendritic spine loss. Pioglitazone inhibited CDK5 activity by decreasing p35 protein level, and improved neuronal long-term potentiation deficit [78, 79].

**TZDS INHIBIT FERROPTOSIS IN AD**

**Discovery of ferroptosis and ACSL4**

Previous studies have used high-throughput screening to identify a small molecule compound, erastin, with a selective lethal ability for RAS mutant tumor cells (RAS-selective lethal, RSL) [80]. Erastin initiated non-apoptotic cell death associated with increased levels of intracellular ROS. It is an iron-dependent lethal mechanism that can be prevented by iron chelation [81]. In 2012, Dixon et al. named this specific cell death induced by erastin as ferroptosis. It was found that erastin inhibits cysteine/glutamate antiporter systemXc\textsuperscript{−}, which results in cystine uptake disorders and impaired glutathione (GSH) synthesis, and ultimately iron-dependent cell death. Ferrostatin-1 (Fer-1) can effectively inhibit erastin-induced ferroptosis but has no significant effect on cystine and glutathione levels. It mainly reduces the levels of lipid ROS and it is speculated that lipid ROS may be crucial for ferroptosis [34]. Further studies revealed that Fer-1 has a lipophilic N-cyclohexyl, which can protect specific membrane PUFAs against ferroptosis-inducing conditions, such as cystine and glutathione depletion. Fer-1 inhibits oxidative damage of membrane PUFAs and resists cell ferroptosis; thus, lipid peroxidation products are the proximate executioners of ferroptosis [35].

RSL3 can also induce ferroptosis, but unlike erastin, it does not depend on systemXc\textsuperscript{−} pathway [81]. RSL3 does not change GSH level and may directly regulate GSH downstream pathway. One consequence of GSH depletion could be glutathione-dependent peroxidases (GPXs) inactivation. Using GSH as an essential cofactor, GPXs catalyze the reduction of peroxide to water or to the corresponding alcohols. It has been suggested that GPX4 is a central regulator of ferroptosis and the direct target of RSL3. GPX4\textsuperscript{−/−} mice developed acute renal failure and significantly increased cellular lipid peroxidation [36, 82, 83]. This is consistent with previous studies showing that GPX4 specifically reduces lipid peroxidation [84]. Meanwhile, a novel small molecule compound liproxstatin-1 (Lip-1) inhibited RSL3-induced ferroptosis in renal tubular epithelial cells and remarkably prolonged the survival of GPX4\textsuperscript{−/−} mice [82]. Like Fer-1, lipophilic free radical-trapping antioxidants, inhibit ferroptosis through a potent reduction of lipid peroxidation [85].

Using a haploid cell line with retroviral-mediated mutations, two specific gene mutations with significant enrichment in ferroptosis-resistant cells, ACSL4 and lysophosphatidylcholine acyltransferase 3 (LPCAT3), were found [86]. Doll et al. applied two approaches: microarray analysis of ferroptosis-resistant cell lines, and a genome-wide CRISPR gRNA library screen. Both approaches identified ACSL4 as a pro-ferroptosis gene and a critical determinant of ferroptosis sensitivity. Acsl4–Gpx4 double-KO cells could be passaged for more than 10 days, which is opposite to previous studies concluding that no cell lines can survive ex vivo without Gpx4 [31]. During PUFAs biosynthesis, ACSL4 preferentially catalyzes arachidonic acid (AA)/adrenic acid (AdA) to form acyl-CoA derivative AA/AdA-CoA, which is esterified to phosphatidylethanolamines (PE) by LPCAT3. It has been found that AA/AdA-CoA containing PE is the preferred substrate for lipid peroxidation in ferroptosis. The content of PE-
AA/AdA in ACSL4 knockout cells was significantly lower than that in WT cells. Loss of ACSL4 significantly inhibited RSL3-induced lipid peroxidation PE-AA/AdA-OH, whereas LPCAT3 knockout only showed a slight protective effect [87].

**AD and ferroptosis**

As early as 1997, it was reported that oxidative damage mediated by iron accumulation is involved in the pathogenesis of AD [88]. The autopsy indicated that iron distribution in the frontal cortex of AD patients is significantly different from that in aging brains without AD [89]. According to NFTs and Aβ plaque levels of the inferior temporal cortex in the autopsy brain, AD neuropathology was divided into low and high pathology scores. The results showed that in subjects with high pathology scores, the cortical iron level was strongly associated with cognitive decline in AD, but there were no significant correlations with non-AD dementia or with increased AD proteinopathy in the absence of dementia. There is a hypothesis that iron does not merely accumulate with AD pathology but rather potentiates degeneration once the pathology is sufficiently severe [18]. The exact relationship between iron accumulation and the development of AD was not understood until the discovery of ferroptosis, which provided new evidence for the involvement of iron accumulation in the cognitive impairment of AD.

**Iron and AD**

Ferroptosis is iron-dependent regulatory cell death. Iron chelator deferroxamine can inhibit ferroptosis [34]. Hepatocyte ferroptosis occurred in mice fed with a high-iron diet and in gene knockout-mediated iron overload mouse models [90]. Iron is a highly redox-reactive metal, and the Fenton reaction is involved in lipid peroxidation by producing hydroxyl radicals. In addition, lipoxygenases (LOXs), iron-containing enzymes, selectively catalyze lipid peroxidation by an iron redox reaction [82, 87].

Iron homeostasis is exquisitely controlled in neurons because of their high metabolic activity. By modulating iron uptake, storage, utilization, and efflux, neurons maintain an optimal intracellular iron balance [91]. Iron homeostasis imbalance in AD leads to iron accumulation in the hippocampus and cortex. Ferroportin (Fpn) is the only known protein that exports intracellular iron in mammals [92]. It was found that Fpn expression is significantly lower in the hippocampus of the AD brain than in the normal brain, resulting in decreased iron efflux capacity and increased iron accumulation in neurons [93, 94]. Elevated levels of ferritin were found in AD brain, providing strong evidence for iron accumulation [95]. Fpn conditional knockout mice developed AD-like hippocampal atrophy, memory deficits, and typical ferroptosis characteristics, confirming that iron accumulation is involved in AD pathogenesis through ferroptosis [94]. Fpn is regulated by AβPP in neurons. AβPP possesses ferroxidase activity, oxidizing Fe^{2+} into Fe^{3+} and interacting with Fpn to export iron [96]. Tau affects the AβPP translocation to the cell surface. Pathological loss of soluble tau can prevent AβPP trafficking to the cell surface in AD, resulting in reduced iron efflux, which causes iron accumulation and ferroptosis (Fig. 3) [97].

**Lipid peroxidation and AD**

The core reaction of ferroptosis is lipid peroxidation, and most ferroptosis inhibitors act as lipophilic radical-trapping antioxidants. Lipid peroxidation can occur through non-enzymatic and enzymatic pathways. The non-enzymatic pathway initiates by the Fenton reaction, which utilizes Fe^{2+} in the labile iron pool (LIP) to react with hydrogen peroxide (H_{2}O_{2}), resulting in the production of hydroxyl radicals (OH•). These radicals remove a bisallylic hydrogen atom from PUFA-PLs to form a carbon-centered phospholipid radical (PL•). Subsequent reactions with molecular oxygen produce phospholipid peroxyl radical (PLOO•), which removes hydrogen from other PUFAs, forming lipid peroxidation PLOOH and the fresh PL•. PLOOH can react with Fe^{2+} to generate PLO•, which damages the peroxidation chain reaction together with PL•, propagating PLOOH on the lipid membrane (Fig. 3) [98, 99]. The primary executioner of the enzymatic processes are LOXs, which catalyze the dioxygenation of PUFAs to produce lipid peroxidation. LOXs-mediated PUFAs oxidation can exert a lethal effect during certain conditions (GSH depletion) [36].

Lipid peroxidation is common in the brain due to high oxygen utilization and high PUFA levels [100]. The evidence of ferroptosis lipid peroxidation, including structural mitochondrial atrophy and increased levels of lipid peroxidation products 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), was found in AD brain by histopathology [95]. The ferroptosis inhibitor, Lip-1, can effectively reduce neuronal death in the hippocampal dentate gyrus and improve learning and memory impair-
Fig. 3. Neuronal ferroptosis mechanism in AD. Overexpressed ACSL4 is activated and catalyzes AA/AdA to AA/AdA-CoA, which is then esterified to PE by LPCAT3. Decreased iron export and increased expression of ferritin promote neuronal iron accumulation. Fe^{2+} in LIP, via the Fenton reactions or ALOXs, catalyzes the production of phospholipid hydroperoxides (PLOOH) and phospholipid radicals (PL•, PLO•, and PLOOH•), leading to neuronal ferroptosis. Neuronal ferroptosis can be prevented by cyst(e)ine–GSH–GPX4 axis and NADH-FSP1-CoQ10 axis.

Peroxidation of membrane lipids can disturb cell membrane integrity, decrease membrane flexibility, increase membrane permeability, and finally affect material transport and signal conduction. In addition, lipid peroxidation may also occur in mitochondria, endoplasmic reticulum, and lysosomes, the organelles rich in phospholipid membranes, leading to cell dysfunction and death [101]. PLOOH can be decomposed into toxic derivatives, such as 4-HNEs and MDA, forming covalent electrophilic products with biological macromolecules, such as DNA, lipids, and proteins. They act as the secondary messengers of oxidative stress. They are also severely cytotoxic [33, 102].

Anti-lipid peroxidation system and AD

In physiological conditions, cells constantly produce ROS and lipid peroxidation products, which are removed by the antioxidant system. Excessive lipid peroxidation often leads to ferroptosis. Cyst(e)ine–GSH–GPX4 axis is the main negative regulator of lipid peroxidation. Cysteine/glutamate antiporter systemXc− is composed of the light-chain subunit, SLC7A11, and the heavy-chain subunit, SLC3A2. Light-chain subunit, SLC7A11, is responsible for cysteine/glutamate transport. SystemXc− uptakes cysteine by exchanging extracellular cysteine for intracellular glutamate, and rapidly reduces it to cysteine. Cysteine is involved in GSH synthesis, which is catalyzed by glutamate cysteine ligase. Cysteine uptake by systemXc− is the ratelimiting step in GSH synthesis [103]. GSH, the cofactor of GPX4, is a crucial antioxidant, which has two forms: reduced GSH and oxidized GSSG. In physiological conditions, GSH is an electron donor for GPX4. As GPX4 is synthesized, selenium replaces the sulfur of cysteine to form selenocysteine (Sec). Active selenol (-SeH) can be oxidized by PLOOH to selenic acid (-SeOH), and then reduced by GSH, which provides two electrons for oxidized GPX4. Glutathione-disulfide reductase (GSR) produces GSH from GSSG [104]. Meanwhile, PLOOH is reduced to the corresponding phospholipid alcohol (PLOH) (Fig. 3) [104, 105].

Another GPX4-independent pathway is mediated by the NADH-FSP1-CoQ10 axis [106]. The N-terminus of FSP1 contains a canonical myristoylation, which binds to the lipid bilayers. On the cell membrane, FSP1 reduces CoQ10 to CoQ10-H2, which captures lipid free radicals and cooperates with GPX4 to resist lipid peroxidation (Fig. 3) [107].

AD is accompanied by excessive lipid peroxidation. There were lower levels of GSH and GPX4 in AD pathology and animal models, which correlate with cognitive dysfunction [94, 95, 108]. Higher SLC7A11 levels were observed in the AD brain com-
pared with the normal brain, which can be related to compensatory intake of cystine to potentiate the anti-lipid peroxidation system [95]. Mutations in presenilin 1 and 2 cause autosomal dominant familial Alzheimer’s disease (FAD). It was found that PS can regulate selenium uptake to promote GPX4 expression and inhibit ferroptosis. PS mutations can disrupt selenium uptake, suppress GPX4 expression, and increase cell sensitivity to ferroptosis. Therefore, presenilin mutations in FAD may promote neurodegeneration by weakening the anti-lipid peroxidation system [109]. GPX4 conditional knockout mice also showed cognitive impairment and hippocampal neuron loss. On the contrary, AD mice overexpressing GPX4 improved significantly, suggesting that ferroptosis plays an important role in AD [110–112].

TZDs inhibit ACSL4 to protect AD from ferroptosis

Accumulating evidence indicates that ferroptosis is an ACSL4-dependent cell death process. ACSL4 activation is dependent on dimerization and regulated by phosphorylated kinases, which include protein kinase A (PKA) and protein kinase C (PKC), a group of Ser/Thr kinases. When Acsl4 was phosphorylated by PKA, its activity was significantly increased compared to the activity of non-phosphorylated Acsl4. On the contrary, PKC phosphorylation caused a significant reduction in the Acsl4 activity [113]. Zhang identified phosphorylation of Thr328 is critical for the activation of ACSL4. One of the five isoforms of PKC, PKCβII could sense the initial lipid peroxidation, directly phosphorylated and activated Acsl4 at Thr328 to increase PUFA-containing phospholipids and promote ferroptosis [114].

The effect of ACSL4 on ferroptosis depends on multiple factors. It has been reported that CD8+T cells can promote tumor cells ferroptosis and mediate anti-tumor immunity by releasing IFNγ [115]. Further studies revealed that IFNγ binds to cell surface receptors and activates JAK/STAT1 signaling pathway to regulate the expression of interferon regulatory factor 1 (IRF1). IRF1 upregulates ACSL4 expression by binding to its promoter region, thereby promoting ferroptosis [116]. In addition, it was found that ACSL4 promoter region has abundant GC boxes, which have a high affinity for the transcription factor SP1. Under hypoxic conditions, upregulation or downregulation of SP1 in intestinal adenocarcinoma cells similarly increased or decreased the expression of ACSL4 [117].

It has been found that the expression of ACSL4 and SP1 is significantly higher in AβPP/PS1 mouse hippocampal neurons than in wild-type mice. In addition, inhibition of ACSL4 or SP1 effectively prevented Aβ-induced ferroptosis of neurons [118, 119]. TZDs specifically inhibit ACSL4-mediated PUFAs activation and lipid peroxidation. Studies have shown that pioglitazone effectively improves cognitive dysfunction by inhibiting lipid peroxidation [120]. Modulating lipid peroxidation and lipid metabolism disorder alleviated cognitive impairment in AD mice [110, 121]. ACSL4 inhibition by TZDs has also been demonstrated in other diseases. In ischemia-reperfusion injury models, including intestinal, lung, brain, and myocardial ischemia models, TZDs or ACSL4 knockout improved ischemia-reperfusion injury by downregulating abnormally overexpressed ACSL4 expression and inhibiting ferroptosis [117, 122–124]. Similarly, TZDs alleviated acute kidney injury and improved rhabdomyolysis by inhibiting ACSL4 [125, 126]. Given the importance of ferroptosis in AD and its dependence on ACSL4, ACSL4 may be a potential target in AD.

CLINICAL TRIALS OF PIOGLITAZONE IN CNS DISEASES

In 1997, the first TZD, troglitazone, was approved in the United States for the treatment of type 2 diabetes. Subsequently, two other TZDs, rosiglitazone and pioglitazone, were successively introduced into the market in 1999. However, because of hepatotoxicity troglitazone was withdrawn from the market in 2000, and rosiglitazone was banned in Europe and the United States in 2010 due to the high risk of myocardial infarction (Fig. 1). Only pioglitazone is still used in clinics [127]. Therefore, in terms of clinical trials, this review mainly describes the use of pioglitazone in CNS diseases.

AD

In an early prospective randomized controlled study, patients with mild AD and type 2 diabetes were treated with pioglitazone or placebo. Both groups also received donepezil and had good glycemic control. The results showed that pioglitazone improved cognitive function and regional cerebral blood flow in the parietal lobe, but the plasma ratio of Aβ40/42 did not significantly change. This study included only 42 cases [128].
In 2014, Read reported an elderly patient with early AD who took a higher dose (45 mg–60 mg) of pioglitazone. Pioglitazone significantly delayed cognitive decline. During the 4-year observation period, the MMSE score showed cognitive improvement and remained constant while taking 60 mg of pioglitazone. When they attempted to reduce the dose to 30 mg, the MMSE score suddenly dropped and improved after adjusting the dose to 45 mg. These findings suggest that pioglitazone may delay cognitive decline in a dose-dependent manner in the early stages of AD [129].

A prospective cohort study compared the incidence of dementia between non-diabetic subjects, diabetic patients not using pioglitazone, diabetic patients with prescriptions of <2 years of pioglitazone, and diabetic with ≥2 years of pioglitazone. The results showed that diabetic patients without the use of pioglitazone had a 23% increase in dementia risk. The use of pioglitazone was associated with a lower risk of dementia, and this protective effect depended on the duration of use. The risk of dementia among diabetic patients with <2 years of using pioglitazone was comparable to those of non-diabetic subjects. The risk of dementia after long-term use of pioglitazone (≥2 years) was 47% less than that among non-diabetic subjects [130].

In a prospective cohort study with metformin as a first-line glucose-lowering regimen, there was a decreased risk of dementia in those taking pioglitazone compared with those taking other second-line glucose-lowering drugs such as sulfonylureas, acarbose, and insulin [131]. A network meta-analysis measured the effects of 6 hypoglycemic agents on AD and mild cognitive impairment (MCI). It showed that pioglitazone 15–30 mg, intranasal insulin 40 units, and sitagliptin 100 mg all significantly improved cognition compared with placebo. In addition, pioglitazone 15–30 mg demonstrated the greatest efficacy [132].

For measuring the safety and efficacy of pioglitazone among non-diabetic subjects with AD, an 18-month, phase II clinical trial was conducted by Takeda Pharmaceuticals. Twenty-five subjects completed the study and 45 mg/day of pioglitazone was well tolerated, with no significant effect on blood glucose levels, hemoglobin levels, or other blood biochemistry [133]. The TOMMORROW study (Fig. 1) was a randomized controlled study consisting of diabetic subjects ≥65 years of age and without cognitive impairment. Participants at high risk of MCI randomly received low-dose pioglitazone (0.8 mg/day) or placebo. The study started in 2013 and terminated in 2018 after failing to meet the expected efficacy. Low doses of pioglitazone did not delay the onset of MCI nor increase the risk of adverse events [134]. The negative results obtained in the TOMMORROW study were related to the use of a lower dose of pioglitazone. In addition, this study did not measure biomarkers, which might affect the effectiveness analysis of the drug.

Ischemic stroke

Ischemic stroke has a high recurrence risk and is the second most common vascular event after myocardial infarction (MI) [135]. Pioglitazone was found as effective as an intensive lipid-lowering strategy in preventing stroke recurrence [136, 137]. A meta-analysis measured the preventive effect of pioglitazone on secondary stroke. It included three randomized controlled studies and found that the use of pioglitazone in patients with stroke, insulin resistance, prediabetes, and diabetes mellitus was associated with a lower risk of recurrent stroke (decreased by 32%) and future major vascular events (decreased by 25%) [138].

The PROactive study, a randomized controlled trial (Fig. 1), included patients with type 2 diabetes who had evidence of macrovascular disease. They received oral pioglitazone or placebo in addition to their glucose-lowering drugs and other medications. After 34 months, pioglitazone significantly reduced the incidence of the primary composite outcome compared with placebo [139]. The second study was published two years later, which showed that pioglitazone significantly reduced the recurrence rate of stroke and cardiovascular events in diabetic patients with prior stroke [140].

Another randomized double-blind controlled trial, the IRIS study (Fig. 1), included non-diabetic subjects with insulin resistance and recent ischemic stroke or TIA. The primary outcome was recurrent stroke or MI. After 4.8 years, the primary outcome occurred in 9.0% of participants in the pioglitazone group and in 11.8% of participants in the placebo group, and the difference was statistically significant [137]. Multiple secondary analyses of the IRIS study were performed. These analyses found that pioglitazone was effective for the secondary prevention of ischemic stroke or TIA and significantly reduced stroke recurrence [141]. After stratifying patients according to their compliance, the results showed that pioglitazone had a better preventive effect on primary
outcomes in subjects with acceptable compliance [142]. Another study stratified patients according to their cardiovascular risk factors and showed that patients at high risk of stroke or MI achieved a greater benefit from pioglitazone [143].

Two retrospective studies confirmed the effect of pioglitazone on the secondary prevention of stroke among diabetic patients with ischemic stroke [144, 145]. Pioglitazone may also have a good preventive effect for primary stroke prevention. Two recent retrospective studies showed that pioglitazone dose-dependently decreased the risk of new-onset ischemic stroke in patients with type 2 diabetes [146, 147].

**Carotid atherosclerosis (coronary artery)**

Pioglitazone has been found to delay the progression of carotid and coronary atherosclerosis in diabetic patients. As measured by ultrasound, carotid intima-media thickness (CIMT) was highly correlated with future risk of cardiovascular events and was a strong predictor of ischemic stroke and MI. Two randomized controlled studies compared the effects of pioglitazone and glimepiride on CIMT in patients with type 2 diabetes [148, 149]. In the CHICAGO study (Fig. 1), participants were asked to adjust their statin dose to meet American Diabetes Association goals before the study. The results showed in the presence of blood pressure and blood glucose control and adequate use of statins, pioglitazone significantly delayed CIMT progression compared with glimepiride. Another study showed that pioglitazone also decelerated the progression of CIMT in patients with prediabetes [150]. The PERISCOPE study compared pioglitazone with glimepiride on coronary atherosclerosis in patients with diabetes. Intravascular ultrasound was used to assess the variation in plaque size (Fig. 1). With comparable levels of blood glucose, the changes in percent atheroma volume and maximum atheroma thickness from baseline to study completion increased in the glimepiride group and decreased in the pioglitazone group. It shows the benefits of pioglitazone in delaying coronary atherosclerosis in patients with type 2 diabetes and coronary artery disease [151].

Atherosclerosis is an inflammatory disease. Each plaque contains numerous macrophages, which weakens plaque stability. In 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging, FDG uptake was correlated with macrophage abundance in plaques. The application of FDG-PET can help identify the inflammatory activity in atherosclerotic plaques [152]. Compared with glimepiride, pioglitazone could attenuate FDG uptake in carotid and coronary atherosclerotic plaques in patients with impaired glucose tolerance or diabetes [153, 154]. In another study comparing statin alone with the combination of statin and pioglitazone, FDG intake was slightly but not significantly lower in the combination group after 3 months of treatment [155].

The vascular endothelium regulates vascular wall homeostasis by maintaining normal vascular tonicity and modulating platelet aggregation and leukocyte adhesion. Endothelial dysfunction is critical for the development of atherosclerosis. Studies have found that pioglitazone improved endothelial vasodilatation in non-diabetic patients, independent of its effect on insulin sensitivity and inflammation [156, 157].

Pioglitazone also altered the lipid profile in the CHICAGO and PERISCOPE studies, with a significant increase in high-density lipoprotein cholesterol (HDL-C) levels and a significant decrease in triglyceride levels [149, 151]. The favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression [158]. The effect of pioglitazone on low-density lipoprotein cholesterol (LDL-C) was reflected in its influence on LDL-C particle size. It was found that pioglitazone can increase LDL-C particle size and reduce particle density, which is associated with slower plaque progression [159]. Small and dense LDL-C particles may promote plaque progression. The measurement of LDL-C particles may be a supplementary risk predictor for people with low LDL-C levels [160].

**LIMITATIONS OF CLINICAL APPLICATION OF PIOGLITAZONE**

Pioglitazone has shown numerous advantages in the preclinical studies and clinical trials of AD with insulin resistance. The clinical application and clinical trials of pioglitazone are limited in non-diabetic subjects with AD due to side effects. Since its approval in the USA, a potential link between pioglitazone and bladder cancer has been the subject of debate. A re-analysis of the PROactive study showed a significantly increased risk of bladder cancer with pioglitazone [161]. After conducting a review of the safety of pioglitazone, the European Medicines Agency (EMA) decided to maintain the marketing of the drug, whereas the US Food and Drug Administration (FDA) warned about the possible increased risk
of bladder cancer. A retrospective cohort study in the UK reached the same conclusion, suggesting that the use of pioglitazone is associated with an increased risk of bladder cancer in patients with type 2 diabetes. The risk of bladder cancer increased with the duration and dose of pioglitazone [162].

On the other hand, pioglitazone may contribute to an increased risk of heart failure by increasing fluid retention. However, the risk of fatal heart failure and all-cause mortality did not increase, and the incidence of cardiovascular events was significantly reduced [163, 164]. In addition, pioglitazone can cause weight gain by redistribution of adipose tissue, and increase the risk of fracture [165, 166]. These adverse events restricted the prescription of pioglitazone, although the overall risk-benefit balance is strongly in favor of prescribing pioglitazone [167].

In patients with diabetes or insulin resistance, the reduced risk of AD with pioglitazone was related not only to its suppressive effects on inflammation and lipid peroxidation but also to its stabilizing effect on glucose metabolism in the brain [134]. The TOMMORROW study was conducted to investigate the efficacy of pioglitazone on non-diabetic patients with AD. In order to achieve good tolerability and safety, a low dose of pioglitazone (0.8 mg/day) was used in the TOMMORROW study. However, low doses of pioglitazone did not delay the onset of MCI in high-risk participants. Previous animal studies suggested that the effect of pioglitazone can be enhanced in a time- and dose-dependent manner [19]. Pioglitazone cannot effectively pass through BBB, and higher doses of pioglitazone are usually used in animal studies to achieve effective concentrations across the BBB. Pioglitazone is an efflux transporter substrate on BBB, preventing pioglitazone from reaching effective concentrations in the brain. The application of lower doses of sustained-release tablets in the TOMMORROW study might keep the transporter in an unsaturated state, and insufficient concentrations of pioglitazone in the brain may be a key factor limiting its efficacy in AD. To address the poor BBB permeability of pioglitazone and its dose-dependent peripheral side effects, intranasal nano lipid carriers of pioglitazone have been formulated for its targeted delivery to the brain [168]. Lertiglitazone, which is the active metabolite products of pioglitazone, is under development by Minoryl for the treatment of X-linked adrenoleukodystrophy (X-ALD) and other neurodegenerative diseases due to its adequate BBB penetration, good bioavailability, and safety profile. Compared with pioglitazone, Lertiglitazone increase 50% brain exposure ratio in mice [169]. In the ADVANCE study, a randomized, double-blind, phase 2-3 trial of lertiglitazone for preventing disease progression in men with adrenomyeloneuropathy. It was found that none of the clinically progressive cerebral adrenoleukodystrophy were occurred in patients receiving lertiglitazone [170]. As increasing the effective concentration of TZDs in the brain, there is still a potential for TZDs in treatment of AD.

CONCLUSION

The growing incidence of AD has brought a tremendous burden to societies and families. People are paying more attention to AD worldwide. Many large pharmaceutical companies are developing drugs for AD; however, there has been no breakthrough in improving the disease outcome. Most of these drugs target Aβ. Although the pathogenesis of AD is still controversial, it can be known that AD is an intricate and multi-factorial pathological process. Drugs that act on a single target or pathway may not be effective in halting AD progression. TZDs, as PPARγ agonists and ACSL4 inhibitors, play a dual role by their potent anti-inflammatory and anti-ferroptosis properties. In the preclinical studies of AD, TZDs simultaneously regulated various pathological pathways, effectively inhibited chronic inflammation, and protected against neuronal loss.

In clinical trials, as a treatment for type 2 diabetes, TZDs effectively controlled blood glucose, improved insulin resistance, and reduced the risk of AD in patients with diabetes or insulin resistance. Low-dose pioglitazone failed to show efficacy in non-diabetic patients with AD. It may be necessary to reduce drug side effects by optimizing drug carriers and improving drug targeting.

AD is the leading cause of dementia, followed by vascular dementia. Autopsy studies found that mixed dementia mediated by these two causes also accounted for a high proportion, which should not be ignored in the treatment of patients who have non-categorized dementia. Clinical trials of pioglitazone have shown its efficacy in the prevention and treatment of arteriosclerosis and ischemic stroke, making it, especially a suitable candidate for mixed dementia.

Currently, among TZDs, only pioglitazone is still used in clinical practice, but many clinicians are discouraged by the increased risk of obesity, fractures, heart failure, and bladder cancer. Although the
results of clinical trials are confusing, the use of pioglitazone for preventing cognitive decline is still a possible long-term option. A careful selection of patients is helpful. Patients with prediabetes or insulin resistance, those with increased risk of myocardial infarction and ischemic stroke, mixed dementia, low risk of heart failure and bladder cancer, can obtain the utmost benefit from pioglitazone.

ACKNOWLEDGMENTS

We appreciated EditSprings (https://www.editsprings.com/) for the expert linguistic services provided.

FUNDING

This work was supported by the International Cooperation Program of Science and Technology Development Plan in Jilin Province (Grant No. 20210402020GH).

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES


betologia 61, 562-573.


